LKT Labs

Biochemicals for Life Science Research

Belinostat

Belinostat

Product ID B1746
Cas No. 414864-00-9
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $127.00 In stock
10 mg $194.00 In stock
Bulk Quote

Quicklinks

Description

Belinostat is a histone deacetylase (HDAC) inhibitor that exhibits antiviral and anticancer chemotherapeutic activities. Belinostat is approved for use in humans in the treatment of T cell lymphoma and is currently in clinical trials as a potential treatment for other leukemias and lymphomas. In pancreatic cancer cells, belinostat induces apoptosis in an AMPK-dependent manner. In other cellular models, this compound decreases HIV release from macrophages by degrading intracellular HIV.

Product Info

Cas No.

414864-00-9
Purity

≥98%
Formula

C15H14N2O4S
Formula Wt.

318.35
IUPAC Name

(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
Synonym

PXD101
Solubility

DMSO 64 mg/mL (201.03 mM) Water Insoluble Ethanol Insoluble
Appearance

Pale yellow powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

B1746 MSDS PDF
Info Sheet

B1746 Info Sheet PDF

References

Campbell GR, Bruckman RS, Chu YL, et al. Autophagy Induction by Histone Deacetylase Inhibitors Inhibits HIV Type 1. J Biol Chem. 2015 Feb 20;290(8):5028-40. PMID: 25540204.

Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2014 Nov 17. [Epub ahead of print].
PMID: 25404094.

Kirschbaum MH, Foon KA, Frankel P, et al. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma. 2014 Oct;55(10):2301-4. PMID: 24369094.

Wang B, Wang XB, Chen LY, et al. Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis. Biochem Biophys Res Commun. 2013 Jul 19;437(1):1-6. PMID: 23743198.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • B0150

    Bambuterol Hydrochloride

    β2-adrenergic agonist, BChE inhibitor.

    ≥98%
  • G7346

    GSK-2636771

    p110β PI3K inhibitor.

    ≥98%
  • C0275

    Castanospermine

    O-GlcNAcase inhibitor.

    ≥98%
  • Z4552

    ZLN005

    PPARγ coactivator-1α expression stimulator.

    ≥98%
  • M5853

    Moniliformin sodium salt

    Mycotoxin produced by species of Fusarium; pote...

    ≥98%
  • T1030

    N-Des-2-methylpropan-2-ol Docetaxel

    N-Des-2-methylpropan-2-ol Docetaxel is an impur...

    ≥90%
  • G4532

    Gliclazide

    Sulfonylurea; SUR1 antagonist.

    ≥98%
  • T2668

    TGR5 Receptor Agonist

    TGR5 agonist.

    ≥99%
  • M5752

    Monastrol

    Pyrimidine derivative; kinesin Eg5 inhibitor.

    ≥95%
  • G4518

    Glucaric Acid Calcium Tetrahydrate

    Oxidized non-cylic hexose sugar.

    ≥98%
  • U682042

    URB602

    Inhibitor of Monoacyglycerol lipase (MAGL).

    ≥98%
  • T7132

    Triacetyl Resveratrol

    Resveratrol prodrug; potential SIRT1 activator....

    ≥99%
  • C5592

    CNX-774

    BTK inhibitor.

    ≥98%
  • C1621

    CEF4

    Peptide, vSrc-induced cytokine.

    ≥95%
  • C3210

    Ciglitazone

    Thiazolidinedione; PPARγ agonist.

    ≥98%
  • A5327

    Anagrelide

    Imidazoquinazoline; PDE3 inhibitor.

    ≥98%
  • G124088

    GDC-1971

    SHP2 inhibitor

    ≥99%
  • E5358

    Enoxacin

    Fluoroquinolone; vacuolar H+ ATPase, topoisomer...

    ≥98%
  • B8278

    Butoconazole Nitrate

    Imidazole; 14-α demethylase inhibitor.

    ≥98%
  • H3277

    Histrelin Acetate

    Peptide, GnRH analog; GnRH agonist.
    ≥95%